Lv11
40 积分 2025-06-19 加入
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
3小时前
待确认
https://www.sciencedirect.com/science/article/abs/pii/S0014299921004398?utm_source=chatgpt.com
5天前
已完结
Autosomal Dominant Polycystic Kidney Disease
1个月前
已完结
Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia
2个月前
已完结
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
2个月前
已完结
Pathophysiological Role of Caveolae in Hypertension
5个月前
已完结
A cytosine deaminase for programmable single-base RNA editing
5个月前
已完结
A quantitative review of nanotechnology‐based therapeutics for kidney diseases
6个月前
已完结
The potential of RNA-based therapy for kidney diseases
6个月前
已完结
Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial
6个月前
已完结
皖公网安备34019202002308
